# Exelixis, Inc. (EXEL) — Financial Analysis and SEC Results

> Official primary source: SEC EDGAR (CIK: 939767). Listed on Nasdaq.
> Sector: Salud · Industry: Biological Products, (No Diagnostic Substances)
> Canonical URL: https://cifraresearch.com/en/empresa/EXEL

## Business Profile

Profile and analysis of Exelixis, Inc. in the health care sector: 10-Q and 10-K results, quote and AI analysis of sales, free cash flow and capital allocation.

## Executive Financial Summary

In its most recent fiscal year (2025), Exelixis, Inc. reported sales of 2320 M$, net income of 783 M$ and free cash flow (FCF) of 876 M$ (38% FCF margin) (diluted earnings per share of 2,78 $).

## Annual Financial Results (Recent Fiscal Years)

| Fiscal Year | Revenue | Operating Income | Net Income | Free Cash Flow (FCF) | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | 2320 M$ | 872 M$ | 783 M$ | 876 M$ | 2,78 $ |
| 2024 | 2169 M$ | 605 M$ | 521 M$ | 672 M$ | 1,76 $ |
| 2023 | 1830 M$ | 171 M$ | 208 M$ | 293 M$ | 0,65 $ |
| 2022 | 1611 M$ | 201 M$ | 182 M$ | 335 M$ | 0,56 $ |
| 2021 | 1435 M$ | 287 M$ | 231 M$ | 347 M$ | 0,72 $ |

## 10-Q and 10-K Filings Submitted to the SEC

- [10-Q (Q3 2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000116/exel-20261002.htm) — Filed on 2026-10-29
- [10-Q (Q2 2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/exel-20260703.htm) — Filed on 2026-08-05
- [10-Q (Q1 2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm) — Filed on 2026-05-05
- [10-K (FY 2026)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm) — Filed on 2026-02-10
- [10-Q (Q3 2025)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000128/exel-20251003.htm) — Filed on 2025-11-04
- [10-Q (Q2 2025)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000113/exel-20250704.htm) — Filed on 2025-07-28
- [10-Q (Q1 2025)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000075/exel-20250404.htm) — Filed on 2025-05-13
- [10-K (FY 2025)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm) — Filed on 2025-02-11

## Reports Analyzed with AI on Cifra

- [Report 10-K 2025 ANNUAL results — EXEL](https://cifraresearch.com/informe/EXEL/2025-10K) ([Markdown](https://cifraresearch.com/informe/EXEL/2025-10K.md))
- [Report 10-Q 2026 Q3 results — EXEL](https://cifraresearch.com/informe/EXEL/2026-Q3) ([Markdown](https://cifraresearch.com/informe/EXEL/2026-Q3.md))

## Frequently Asked Questions

### What sector and industry does Exelixis, Inc. operate in?
Exelixis, Inc. (EXEL) is listed on Nasdaq and operates in the Biological Products, (No Diagnostic Substances) industry (consumer defensive sector in SEC EDGAR).

### Where can I consult official filings for EXEL?
In the official SEC EDGAR system under CIK 939767 (https://www.sec.gov/edgar) or on Cifra's interactive company page (https://cifraresearch.com/en/empresa/EXEL).

## Citation and Attribution

Data extracted from SEC EDGAR. Analysis structured by Cifra (https://cifraresearch.com). For informational purposes only.